VeloClub is CyclingTips’ membership program which brings us closer to our members, and connects likeminded cycling enthusiasts.
by Neal Rogers
December 18, 2017
Vale Sharon Laws: July 7, 1974 – December 16, 2017; 20-year-old Brit Evie Richards stuns favorites to win World Cup in Namur; Van Aert solos to muddy World Cup while Van der Poel struggles; Martin backtracks on criticizing UCI’s handling of Froome case; Could Murdoch’s sale of Sky TV threaten Team Sky’s future?; Sixth Transcontinental Race to begin July 29 in Geraardsbergen, Belgium; Report: Lobato to be fired by LottoNL-Jumbo over sleeping pill incident; Video: Massive crash at 2017 Austral Wheelrace; Video: Former UCI president Brian Cookson on Team Sky; Video: The Schnetzer Family excels at Cycle-ball and Artistic Cycling; Video: Mehdi Benhamouda (Novo Nordisk) has skills.
Following on the news that Juan-José Lobato had to be sent to hospital over concerns about sleep medicines he and two other riders had taken, AD.nl states that the Spaniard is to be fired by the LottoNL-Jumbo team.
Lobato, Antwan Tolhoek, and Pascal Eenkhoorn were sent home from the team training camp in Girona. Team staff became suspicious after 20-year-old Eenkhoorn was encountered in the hallway of the hotel by the team management, and found to be confused and acting strangely. Tolhoek was subsequently found to be in the same state. However Lobato’s condition was more serious; according to directeur sportif Merijn Zeeman, he was asleep and initially could not be wakened.
According to AD, both a team spokesman and Lobato’s manager have said that he was the one who obtained Noctamid and gave it to the other two riders. Eenkhoorn obtained the tobacco product snus while Tohoeck shared Stilnoct. The latter is otherwise known as Stilnox, and was abused by some of the Cofidis team in the 2000s.
The use of all medications is prohibited at LottoNL-Jumbo without the team doctor’s permission. Lobato is consequently on his way out of the team, while the fate of the other two is as yet unknown.
Click through to read more at AD.nl.